JP2024521578A - 結晶性ａｂｄｎａｚ組成物ならびにその作製方法及び使用方法 - Google Patents

結晶性ａｂｄｎａｚ組成物ならびにその作製方法及び使用方法 Download PDF

Info

Publication number
JP2024521578A
JP2024521578A JP2023575588A JP2023575588A JP2024521578A JP 2024521578 A JP2024521578 A JP 2024521578A JP 2023575588 A JP2023575588 A JP 2023575588A JP 2023575588 A JP2023575588 A JP 2023575588A JP 2024521578 A JP2024521578 A JP 2024521578A
Authority
JP
Japan
Prior art keywords
cancer
abdnaz
composition
subject
sensitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521578A5 (https=
Inventor
ティー． オロンスキー，ブライアン
アール． リード，トニー
ラーソン，クリストファー
カンター，ジェームズ
Original Assignee
エピセントアールエックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピセントアールエックス，インコーポレイテッド filed Critical エピセントアールエックス，インコーポレイテッド
Publication of JP2024521578A publication Critical patent/JP2024521578A/ja
Publication of JP2024521578A5 publication Critical patent/JP2024521578A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
JP2023575588A 2021-06-09 2022-06-09 結晶性ａｂｄｎａｚ組成物ならびにその作製方法及び使用方法 Pending JP2024521578A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208631P 2021-06-09 2021-06-09
US63/208,631 2021-06-09
PCT/US2022/032780 WO2022261284A1 (en) 2021-06-09 2022-06-09 Crystalline abdnaz compositions and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2024521578A true JP2024521578A (ja) 2024-06-03
JP2024521578A5 JP2024521578A5 (https=) 2025-06-17

Family

ID=84425536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575588A Pending JP2024521578A (ja) 2021-06-09 2022-06-09 結晶性ａｂｄｎａｚ組成物ならびにその作製方法及び使用方法

Country Status (12)

Country Link
US (1) US20240293360A1 (https=)
EP (1) EP4351567A4 (https=)
JP (1) JP2024521578A (https=)
KR (1) KR20240019798A (https=)
CN (1) CN117835979A (https=)
AU (1) AU2022289720A1 (https=)
BR (1) BR112023025535A2 (https=)
CA (1) CA3221351A1 (https=)
IL (1) IL309043A (https=)
MX (1) MX2023014676A (https=)
TW (1) TW202313001A (https=)
WO (1) WO2022261284A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069420A (zh) 2016-01-11 2018-12-21 埃皮辛特瑞柯斯公司 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
WO2023178283A1 (en) * 2022-03-18 2023-09-21 Epicentrx, Inc. Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507842B2 (en) * 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US8471041B2 (en) 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
CN109069420A (zh) 2016-01-11 2018-12-21 埃皮辛特瑞柯斯公司 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法
US11510901B2 (en) * 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection

Also Published As

Publication number Publication date
TW202313001A (zh) 2023-04-01
AU2022289720A1 (en) 2023-12-21
US20240293360A1 (en) 2024-09-05
EP4351567A1 (en) 2024-04-17
KR20240019798A (ko) 2024-02-14
IL309043A (en) 2024-02-01
WO2022261284A1 (en) 2022-12-15
MX2023014676A (es) 2024-02-06
CN117835979A (zh) 2024-04-05
CA3221351A1 (en) 2022-12-15
BR112023025535A2 (pt) 2024-02-27
EP4351567A4 (en) 2025-04-16

Similar Documents

Publication Publication Date Title
JP2024521578A (ja) 結晶性ａｂｄｎａｚ組成物ならびにその作製方法及び使用方法
US12583865B2 (en) Biologically active taxane analogs and methods of treatment by oral administration
EP3224254B1 (de) Substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln
EP3237416B1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3883651A1 (en) Compounds and compositions for treating conditions associated with sting activity
WO2015196137A1 (en) Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5] pyrazino [2,1-b] [1,3] oxazepine-10-carboxamide
EP3953337A1 (en) Degraders of kelch-like ech-associated protein 1 (keap1)
JP2022136163A (ja) Ｄｎａ損傷剤とｄｎａ－ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
JP2025511974A (ja) がんの治療のためのラクテート／ＡＴＰ産生阻害剤としてのＮ－（３－（ベンゾ［ｂ］チオフェン－２－カルボキシアミド）－フェニル）－２，３－ジヒドロベンゾ［ｂ］［１，４］ジオキシン－６－カルボキシアミド誘導体及び関連化合物
JP7299411B2 (ja) アデノシン受容体拮抗薬
WO2011028571A1 (en) Taxane analogues, their use, pharmaceutical compositions containing them, and processes for their preparation
TW202218660A (zh) Sarm1酶活性抑制劑及其在神經退行性疾病中的應用
US20260035346A1 (en) Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods
CN110981888B (zh) N-芳基二硫吡咯酮脲类和氨基酯类衍生物及其制备和应用
US11873308B2 (en) Biologically active taxane analogs and methods of treatment by oral administration
WO2025059081A1 (en) Bicyclic compounds for restoring mutant p53 function
CN102988349A (zh) Aphanamixoid A在制备抗血小板聚集药物中的应用
HK40114515A (zh) (s)-1-((2'，6-双(二氟甲基)-[2，4'-联吡啶]-5-基)氧基)-2，4-二甲基戊-2-胺及其盐的固体形式
WO2006107478A2 (en) Crystalline sodium salt of an hiv integrase inhibitor
JPS58154574A (ja) アルキレンジオキシベンゼン誘導体およびその酸付加塩

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250609